Pharmaceutical Technology19m
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Actuate Therapeutics has gained OMPD from the EMA for elraglusib aimed at treating pancreatic ductal adenocarcinoma (PDAC).
Pharmaceutical Technology3h
FDA awards GSA breakthrough status for relapsed osteosarcoma treatment
GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.
Pharmaceutical Technology4h
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease
Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).
Pharmaceutical Technology21h
Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment
Variant has entered a multi-year research partnership with Novo Nordisk to identify new targets to treat metabolic conditions.